1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   
   
3. Who will be able to view these files?
   Response - Researchers who provide a methodologically sound proposal.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [rohitbhatia71@yahoo.com].
   


6. For how long will this data be available start date provided 20-02-2001 and end date provided 02-01-1970?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Acute ischemic stroke (AIS) due to large vessel occlusions (LVO) is a serious and potentially  disabling situation. Although there have been issue with terminology, blockages of the intracranial internal carotid artery (ICA), proximal posterior, middle, and anterior cerebral arteries (PCA, MCA, and ACA, respectively), intracranial vertebral artery (VA), and/or basilar artery (BA) are commonly referred to as large vessel occlusions (LVOs). Accounting for up to 46% of acute ischemic strokes (AISs), LVOs possess outsized clinical importance as they more than doubled the risk of death or dependence as compared to non-LVO AISs in the pre-endovascular era. Rapid and timely treatment with intravenous (IV) thrombolysis and endovascular treatment (EVT) leading to vessel recanalization improves patient outcomes significantly and bridging therapy is the current standard of care in comprehensive stroke centres across the world and in India.  However, an incompletely answered question is whether one thrombolytic agent is better over another during the bridging therapy. There has been a debate if Tenecteplase (TNK) is superior to rTPA  (recombinant tissue plasminogen activator, Alteplase) as a thrombolytic agent. The current study aims to understand if one agent is superior to the other during bridging therapy in the treatment of AIS due to LVO’s. Eligible patients with AIS and LVO, presenting within 4.5 hours, will be randomised to either receive rTPA or TNK in standard doses before undergoing endovascular thrombectomy. Primary outcomes include Proportion of patients who will be independent at 3 months ( using modified Rankin score; mRS less than or equal to 2 taken as a good outcome) and proportion of patients who achieve recanalization TICI grade 2b or 3 at first angiography run and end of the EVT procedure. Secondary outcomes include proportion of patients with early Neurological improvement (ENI) defined as improvement of NIHSS by 4 points at 24 hours, rate of symptomatic ICH as defined using SITS MOST criteria, rate of any ICH, rate of any systemic major or minor bleeding using GUSTO classification, and duration of hospital stay.